Form 4: Spyre Therapeutics CEO Sells Shares Under 10b5-1 Plan

Spyre Therapeutics CEO Cameron Turtle sold 15,000 shares of common stock on January 2, 2026, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Cameron Turtle, CEO and Director of Spyre Therapeutics, Inc. (SYRE), sold a total of 15,000 shares of common stock on January 2, 2026.
• The sales were executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025.
• The shares were sold in three separate transactions at weighted average prices of $30.47, $31.79, and $32.39.
• Specifically, 12,709 shares were sold at an average price of $30.47, 2,191 shares at an average price of $31.79, and 100 shares at an average price of $32.39.
• Following these transactions, Cameron Turtle beneficially owns 671,907 shares of Spyre Therapeutics common stock.
• The remaining beneficial ownership includes 159,713 shares that vest in monthly installments over approximately one year, contingent on continued service.

Sentiment

Score: 4

Explanation: The sentiment is neutral to slightly negative. While the sale is pre-planned under a 10b5-1, a CEO selling shares can sometimes be interpreted as a lack of strong conviction, even if for personal financial management. The amount sold is not insignificant relative to the total beneficial ownership, but it's a planned transaction.

Negatives

• A significant insider sale by the CEO could be perceived negatively by investors, potentially signaling a lack of confidence or a desire to diversify holdings.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

This Form 4 filing reports an individual insider transaction and does not provide broader industry context or trends. Insider sales, especially those under a 10b5-1 plan, are common and can be for personal financial planning reasons unrelated to company performance.

Stakeholder Impact

• Shareholders may view the CEO's sale of shares with caution, potentially interpreting it as a signal, despite the 10b5-1 plan. This could lead to minor short-term price volatility or increased scrutiny of the company's performance.

Key Dates

Recommendation

The filing details a pre-planned insider stock sale by the CEO, which is a routine event for executives managing personal finances. It does not provide new information about the company's operational performance, strategic direction, or financial health that would warrant a change in investment recommendation. Therefore, a 'hold' recommendation is appropriate, maintaining current positions while awaiting more substantive company updates.

Keywords

Spyre Therapeutics, SYRE, Cameron Turtle, Insider Trading, Form 4, Stock Sale, 10b5-1 Plan, CEO, Director, Equity Sales